Geographical differences in the management of metastatic de novo renal cell carcinoma in the era of immune-combinations.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Porta Camillo, Bamias Aristotelis, Zakopoulou Roubini, Myint Zin W, Cavasin Nicolò, Iacovelli Roberto, Pichler Martin, Kopecky Jindrich, Kucharz Jakub, Rizzo Mimma, Galli Luca, Büttner Thomas, DE Giorgi Ugo, Kanesvaran Ravindran, Fiala Ondřej, Grande Enrique, Zucali Paolo A, Kopp Ray M, Fornarini Giuseppe, Bourlon Maria T, Scagliarini Sarah, Molina-Cerrillo Javier, Aurilio Gaetano, Matrana Marc R, Pichler Renate, Cattrini Carlo, Büchler Tomáš, Massari Francesco, Mollica Veronica, Seront Emmanuel, Calabrò Fabio, Pinto Alvaro, Berardi Rossana, Zgura Anca, Mammone Giulia, Ansari Jawaher, Atzori Francesco, Chiari Rita, Caffo Orazio, Procopio Giuseppe, Sunela Kaisa, Bassanelli Maria, Ortega Cinzia, Grillone Francesco, Landmesser Johannes, Merler Sara, Messina Carlo, Küronya Zsófia, Mosca Alessandra, Bhuva Dipen, Santini Daniele, Vau Nuno, Morelli Franco, Incorvaia Lorena, Rebuzzi Sara E, Roviello Giandomenico, Soares Andrey, Zabalza Ignacio O, Rizzo Alessandro, Bisonni Renato, Pierantoni Francesco, Sorgentoni Giulia, Monteiro Fernando S, Battelli Nicola, Buti Sebastiano, Santoni Matteo
Аннотация
METHODS: We conducted a multicenter retrospective observational study in mRCC patients treated with first-line immune combinations from 55 centers in 19 countries. From 1152 patients in the ARON-1 dataset, we selected 651 patients with de novo mRCC. 255 patients (39%) had undergone CN, partial in 14% and radical in 86% of cases; 396 patients (61%) received first-line immune-combinations without previous nephrectomy.
RESULTS: Median overall survival (OS) from the diagnosis of de novo mRCC was 41.6 months and not reached (NR) in the CN subgroup and 24.0 months in the no CN subgroup, respectively (P<0.001). Median OS from the start of first-line therapy was NR in patients who underwent CN and 22.4 months in the no CN subgroup (P<0.001). Patients who underwent CN reported longer OS compared to no CN in all the three geographical areas.
CONCLUSIONS: No significant differences in terms of patients' outcome seem to clearly emerge, even if the rate CN and the choice of the type of first-line immune-based combination varies across the different Cancer Centers participating in the ARON-1 project.